Stocks Health care DRMA
NASDAQ · Health careDermata Therapeutics, Inc. (DRMA)
It posted a net loss of $8.4M. At June 30, 2026 it held $4.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Dermata Therapeutics, Inc.
- Net worth
- Dermata Therapeutics, Inc. has a market value (market cap) of $2.7M at the latest share price, and shareholders' equity of $3.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $7.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dermata Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Dermata Therapeutics, Inc. does
Dermata Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DRMA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$7.6M | -$8.16 | n/a |
| 2024 | n/a | -$12.3M | -$80.32 | n/a |
| 2023 | n/a | -$7.8M | -$400.00 | n/a |
| 2022 | n/a | -$9.6M | -$2,085.39 | n/a |
| 2021 | n/a | -$7.9M | -$5,824.71 | n/a |
| 2021 | n/a | -$3.2M | -$4,050.93 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Dermata Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 17, 2026Delisting notice 25-NSE
- August 17, 2026
- August 11, 2026
- August 11, 2026
- August 5, 2026Other event 8-K
- June 4, 2026
- June 1, 2026Activist stake (5% or more) SCHEDULE 13D
- May 27, 2026
- May 22, 2026
- May 13, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Dermata Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 16, 2026 | Van Hoose Kyri K.SVP, CFO | Received as pay | 102,040 | - |
| August 16, 2026 | Proehl Gerald TPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Received as payindirect | 170,068 | - |
| June 16, 2026 | Scott Kathleen D.Director | Sold | 11 | $13.1 |
| February 17, 2026 | Bedoya-Toro Munera Maria ESVP, Regulatory Affairs | Bought | 1,000 | $1.3K |
| December 23, 2025 | Proehl Gerald TPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Received as payindirect | 490,196 | - |
| December 23, 2025 | Proehl Gerald TPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | Received as payindirect | 122,549 | - |
| December 23, 2025 | Van Hoose Kyri K.SVP, CFO | Received as pay | 122,549 | - |
Who owns DRMA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Proehl Gerald T13D, may seek influence | 17.3% | February 23, 2026 |
| Kyri K. Van Hoose13D, may seek influence | 9% | June 1, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 526,106 shares in total, about $353.3K at the last price.
| Holder | Shares |
|---|---|
| Proehl Gerald TPRESIDENT, CHAIRMAN, CEO, Director, 10% owner | 292,631292,631 held indirectly |
| Van Hoose Kyri K.SVP, CFO | 232,463 |
| Bedoya-Toro Munera Maria ESVP, Regulatory Affairs | 1,012 |
Questions about DRMA
What does Dermata Therapeutics, Inc. do?
Dermata Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DRMA. Its shares trade on NASDAQ under the ticker DRMA.
What is Dermata Therapeutics, Inc.'s net worth?
Dermata Therapeutics, Inc. has a market value (market cap) of $2.7M at the latest share price, and shareholders' equity of $3.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dermata Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $8.4M.
When did Dermata Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
When is Dermata Therapeutics, Inc.'s next earnings report?
Dermata Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DRMA with
Follow DRMA
Get an email when Dermata Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dermata Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.